Adjunctive TNF inhibition with standard treatment enhances bacterial clearance in a murine model of necrotic TB Granulomas

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Skerry, Ciaran ^a   Harper, Jamie ^a   Klunk, Mariah ^a   Bishai, William R ^a,b,c   Jain, Sanjay K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AFRICA HEALTH RESEARCH INSTITUTE   (South Africa)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL CLEARANCE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HOST RESISTANCE; LUNG GRANULOMA; LUNG TUBERCULOSIS; MONOTHERAPY; MOUSE; NONHUMAN; PATHOGEN LOAD; RELAPSE; TREATMENT DURATION;

BACTERIA (MICROORGANISMS); MURINAE; MUS; MYCOBACTERIUM TUBERCULOSIS;

EID: 84862980932     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039680     Document Type: Article

References (28)

1. Dye C, Williams BG, (2008) Eliminating human tuberculosis in the twenty-first century. J R Soc Interface 5: 653 662.
2. Haapanen JH, Kass I, Gensini G, Middlebrook G, (1959) Studies on the gaseous content of tuberculous cavities. Am Rev Respir Dis 80: 1 5.
3. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, (2003) American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 167: 603 662.
4. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2: 561 572.
5. Senaldi G, Yin S, Shaklee CL, Piguet PF, Mak TW, (1996) Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNF-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 157: 5022 5026.
6. Kindler V, Sappino AP, Grau GE, Piguet PF, Vassalli P, (1989) The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56: 731 740.
7. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098 1104.
8. MMWR (2004) Tuberculosis associated with blocking agents against tumor necrosis factor-alpha-California, 2002-2003. MMWR Morb Mortal Wkly Rep 53: 683 686.
9. Paige C, Bishai WR, (2010) Penitentiary or penthouse condo: the tuberculous granuloma from the microbe's point of view. Cell Microbiol 12: 301 309.
10. Bekker LG, Maartens G, Steyn L, Kaplan G, (1998) Selective increase in plasma tumor necrosis factor-alpha and concomitant clinical deterioration after initiating therapy in patients with severe tuberculosis. J Infect Dis 178: 580 584.
11. Wallis RS, van Vuuren C, Potgieter S, (2009) Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 48: 1429 1432.
12. Wallis RS, (2005) Reconsidering adjuvant immunotherapy for tuberculosis. Clin Infect Dis 41: 201 208.
13. Blackmore TK, Manning L, Taylor WJ, Wallis RS, (2008) Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis 47: e83 85.
14. Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, et al. (2004) A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 18: 257 264.
15. Pan H, Yan BS, Rojas M, Shebzukhov YV, Zhou H, et al. (2005) Ipr1 gene mediates innate immunity to tuberculosis. Nature 434: 767 772.
16. Harper J, Skerry C, Davis SL, Tasneen R, Weir M, et al. (2012) Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 205: 595 602.
17. Hu YL, Kim HY, Kohno T, Khare SD, (2007) Pharmacodynamic effects of the murine p75-Fc fusion protein in mice. J Investig Dermatol Symp Proc 12: 50 51.
18. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO, (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38: 1261 1265.
19. Plessner HL, Lin PL, Kohno T, Louie JS, Kirschner D, et al. (2007) Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 195: 1643 1650.
20. Espevik T, Nissen-Meyer J, (1986) A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. J Immunol Methods 95: 99 105.
21. Lories RJ, Derese I, de Bari C, Luyten FP, (2007) Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 56: 489 497.
22. Caccamo N, Guggino G, Meraviglia S, Gelsomino G, Di Carlo P, et al. (2009) Analysis of Mycobacterium tuberculosis-specific CD8 T-cells in patients with active tuberculosis and in individuals with latent infection. PLoS ONE 4: e5528.
23. Cox JH, Ivanyi J, (1988) The role of host factors for the chemotherapy of BCG infection in inbred strains of mice. APMIS 96: 927 932.
24. Koo MS, Manca C, Yang G, O'Brien P, Sung N, et al. (2011) Phosphodiesterase 4 inhibition reduces innate immunity and improves isoniazid clearance of Mycobacterium tuberculosis in the lungs of infected mice. PLoS ONE 6: e17091.
25. Maiga M, Agarwal N, Ammerman NC, Gupta R, Guo H, et al. (2012) Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse Model. PLoS ONE 7: e30749.
26. Subbian S, Tsenova L, O'Brien P, Yang G, Koo MS, et al. (2011) Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology. Am J Pathol 179: 289 301.
27. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, et al. (2009) The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 60: 1895 1905.
28. Sweeny DJ, Li W, Clough J, Bhamidipati S, Singh R, et al. (2010) Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation. Drug Metab Dispos 38: 1166 1176.